Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine

Lancet. 1983 Nov 12;2(8359):1099-102. doi: 10.1016/s0140-6736(83)90624-4.


A randomised blind controlled trial of hepatitis B immune globulin (HBIG) plus hepatitis B vaccine for the prevention of the perinatally transmitted HBsAg carrier state was conducted in Taipei. Infants of e-antigen-positive HBsAg carrier mothers were given HBIG immediately after birth, and then one of three schedules of vaccination. There was no difference in efficacy between the three schedules; the combined efficacy was 94%, compared with that of HBIG alone (71%) or of vaccination alone (75%). Persistent HBs antigenaemia developed in only 9 (6%) of the 159 infants receiving prophylaxis, but in 88% of the controls. Antibodies developed in all those who did not become antigenaemic and presumably will provide long-term protection from hepatitis B virus infection. HBIG should be given as soon as possible after birth and need not be given again if the infant is subsequently vaccinated. With HBIG coverage from birth, the timing of the start of vaccination does not seem to be of importance within the first month of life, but to maximise compliance and minimise costs hepatitis B vaccination should be initiated during the confinement.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carrier State / prevention & control
  • Clinical Trials as Topic
  • Double-Blind Method
  • Female
  • Follow-Up Studies
  • Hepatitis B / prevention & control*
  • Hepatitis B / transmission
  • Hepatitis B Antibodies / analysis
  • Hepatitis B e Antigens / analysis
  • Hepatitis B virus / immunology*
  • Humans
  • Immunization, Passive*
  • Infant
  • Infant, Newborn
  • Maternal-Fetal Exchange
  • Pregnancy
  • Viral Vaccines*


  • Hepatitis B Antibodies
  • Hepatitis B e Antigens
  • Viral Vaccines